Gail Edwards

Gail Edwards

Auto-generated profile, based on publicly available information

Gail Edwards

Pharmacy Department Alfred Health Melbourne Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Trauma & Case Reports
Verified
Journal Article
Open access
GEGail Edwards
Gail Edwards
CRCristina Roman
Cristina Roman
RJRondhir Jithoo
Rondhir Jithoo
BMBiswadev Mitra
Biswadev Mitra
Idarucizumab is the first effective humanized monoclonal antibody fragment developed specifically as a reversal agent for dabigatran, a Direct Oral Anticoagulant. Despite recent trials demonstrating reversal of clinically relevant bleeding, there is a paucity of data on use outside the trial setting. This manuscript describes the use of Idarucizumab to reverse dabigatran in two patients presenting to the emergency department of a major tertiary hospital with acute traumatic subdural haematomas (SDH). Patients were identified through retrospective review of medication dispensing systems and electronic medical records. Two cases of Idarucizumab use were identified. Case 1 was of a 63-year-old male who presented following a motorcycle crash. Case 2 was of a 77-year-old male who presented with a 3-week history of ataxia and recurrent falls. Both patients were taking dabigatran for atrial fibrillation (AF). CT Brain revealed acute SDH with clinical indications for urgent surgical evacuation. Serum dabigatran levels were obtained on arrival in the emergency department with levels of 155 ng/ml and 110 ng/ml (reference range 117-275 ng/ml). Idarucizumab for dabigatran reversal was commenced; Case 1 received 5 g Idarucizumab as an intravenous bolus dose, while Case 2 received 5 g Idarucizumab as two 2.5 g intravenous infusions. Serum dabigatran levels for Cases 1 and 2 were 0 ng/ml at 75 min and 340 min post Idarucizumab administration respectively. Both patients proceeded to craniotomy with evacuation of the SDH. There was no extension of the SDH in either case. Anticoagulation was withheld until outpatient clinic review, and both patients transferred for rehabilitation prior to discharge home. Idarucizumab was clinically effective for reversing dabigatran, resulting in undetectable serum levels, and should be considered in patients presenting to hospital with clinically significant bleeding associated with dabigatran therapy.

8 July 2022 in Australian Journal of Rural Health
Verified
Journal Article
Closed access
ETErica Y. Tong
Erica Y. Tong
PHPhuong U. Hua
Phuong U. Hua
GEGail Edwards
Gail Edwards
EDEleanor Van Dyk
Eleanor Van Dyk
GYGary Yip
Gary Yip
MDMichael J. Dooley
Michael J. Dooley

23 June 2023 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
ETErica Y Tong
Erica Y Tong
GEGail E Edwards
Gail E Edwards
PHPhuong Uyen Hua
Phuong Uyen Hua
BMBiswadev Mitra
Biswadev Mitra
EDEleanor Van Dyk
Eleanor Van Dyk
MDMichael J Dooley
Michael J Dooley
Aim: Partnered Pharmacist Medication Charting (PPMC) in patients admitted under general medical units has been shown to reduce medication errors. The aim of this study is to evaluate the impact of the PPMC model on medication errors in patients admitted under cancer units in Victorian hospitals. Methods: A prospective cohort study comparing cohorts before and after the introduction of PPMC was conducted. This included a 2-month pre-intervention phase and 3-month intervention phase. PPMC was implemented during the intervention phase as new model of care that enabled credentialed pharmacists to chart all admission medications, including pre-admission or new medications and cancer therapies, in collaboration with the admitting medical officer. The proportion of medication charts with at least one error was the primary outcome measure. Results: Seven health services across Victoria were included in the study. The majority of health services were using paper-based prescribing systems for oncology. Of the 547 patients who received standard medical medication charting, 331 (60.5%) had at least one medication error identified compared to 18 out of 416 patients (4.3%) using the PPMC model (p < 0.001). The median (interquartile range) inpatient length of stay was 5 (2.9–10.6) days in pre-intervention and 4.9 (2.9–11) days in intervention (p = 0.88). In the intervention arm, 42 patients had cancer therapy charted by a pharmacist with no errors. Conclusions: PPMC was successfully scaled into cancer units as a collaborative medication safety strategy. The model was associated with significantly lower rates of medication errors, including cancer therapies. PPMC should be adopted more widely in cancer units in Australia.

31 January 2024 in Journal of Pharmacy Practice and Research
Verified
Journal Article
Closed access
LCLauren Crawley
Lauren Crawley
GEGail Edwards
Gail Edwards
HGHarry Gibbs
Harry Gibbs
ETErica Tong
Erica Tong